Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/hepr.13541 http://scihub22266oqcxt.onion/10.1111/hepr.13541 32583525!7361293!32583525     free     free     free       Hepatol+Res 2020 ; 50 (9): 1004-1014 Nephropedia Template TP {{tp|p=32583525|t=2020. Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC |pdf=|usr=}}{{32583525}} gab.com Text Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC JO: Hepatol Res http://www.kidney.de/pget.php?&tw=1&pmid=32583525 #FOAvip This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections. Twit Text FOAVip Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC ????Hepatol Res http://www.kidney.de/pget.php?&tw=1&pmid=32583525 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32583525 #FOAvip English Wikipedia <ref>{{Cite pmid|32583525}}</ref> Treatment of hepatocellular carcinoma during the COVID-19 outbreak: The Working Group report of JAMTT-HCC #MMPMID32583525 Kudo M; Kurosaki M; Ikeda M; Aikata H; Hiraoka A; Torimura T; Sakamoto N Hepatol Res 2020[Sep]; 50 (9): 1004-1014 PMID32583525show ga This contingency guide was formulated on the premise that delivering standard treatment for hepatocellular carcinoma (HCC) has come under strain due to the coronavirus (COVID-19) pandemic. Measures required are likely to vary largely across regions and individual institutions, depending on the level of the strain imposed by the pandemic (e.g., number of inpatients infected with COVID-19 and the availability of resources, including personal protective equipment and inpatient beds). In addition, models suggest that the second and third waves of COVID-19 will occur before effective vaccines and medicines become widely available in Japan (expected time, 2-3 years). This guide should serve as a good reference for best practices in the management of HCC, which is in light of the possible risk of impending collapse of the healthcare system due to a surge in COVID-19 infections. ?Treatment of hepatocellular carcinoma during the COVID-19 outbreak: Th(epmc).pdf DeepDyve Pubget Overpricing